搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
1 小时
EMA’s PRAC starts semaglutide review
Pharmacovigilance Risk Assessment Committee (PRAC) has started a review of medicines containing semaglutide following ...
The Pharma Letter
2 小时
Atara down 41% on Ebvallo CRL
T-cell immunotherapy company Atara Biotherapeutics (Nasdaq: ATRA) closed 41% lower on Friday.
The Pharma Letter
3 小时
Orna and Simnova expand RNA therapy collaboration
Orna Therapeutics and Shanghai Simnova expand their collaboration to develop RNA-based therapies targeting BCMA for multiple ...
The Pharma Letter
3 小时
Boehringer’s iclepertin Phase III program in schizophrenia misses goals
German family-owned pharma major Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical ...
The Pharma Letter
4 小时
FDA grants full approval for AstraZeneca's Calquence
The FDA grants AstraZeneca’s Calquence full approval for first-line mantle cell lymphoma as a combination therapy and ...
The Pharma Letter
4 小时
China greenlight for Innovent and ASK Pharm’s limertinib
China's National Medical Products Administration (NMPA) has approved the New Drug Application (NDA) of limertinib for the ...
The Pharma Letter
4 小时
Indian pharma companies ignite innovation in diabetes
Even as the global diabetes war continues to rage, Indian pharmaceutical companies are emerging from the shadows, armed with ...
The Pharma Letter
21 小时
CymaBay’s Livdelzi approved by MHRA
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today, approved Livdelzi (seladelpar), developed by ...
The Pharma Letter
21 小时
Latin America's major 2025 challenges for securing population-wide access to innovative ...
Despite the strategies and programs that have been implemented to bring effective and equitable access to new medicines and ...
The Pharma Letter
22 小时
Neuromuscular disease market poised for rapid growth
The neuromuscular disease therapeutics market is projected to grow by $13.7B from 2025 to 2029, driven by advancements in AI, ...
The Pharma Letter
1 天
Servier expands partnership with Google on AI
Servier and Google Cloud expand their partnership to integrate AI and generative AI in drug R&D, focusing on rare diseases.
The Pharma Letter
1 天
Truveta Genome Project aims to create world’s largest genetic database
US health systems and Regeneron Genetics Center launch the Truveta Genome Project, a $320M initiative to sequence up to 10M ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈